Effects of Integrative Medicine on Infectious Respiratory Diseases Including COVID-19 (AtemNHK)

Effects of Interventions and Lifestyle Modifications in Integrative Medicine and the Course of Infectious Respiratory Diseases Including COVID-19

The outbreak of the novel coronavirus SARS-CoV-2 caused a health emergency of international proportions when it was declared by the World Health Organization (WHO) in January 2020. Since then, the virus has spread internationally and the WHO has classified the outbreak as a pandemic. In the context of the increasing reporting of this pandemic and the increasing governmental measures to limit or slow down the spread of SARS-CoV-2 by all means, there is so far little scientific evidence for the effects of a healthy lifestyle on the disease. The aim of this study is to compare the potential of different, possibly protective lifestyles using the example of the COVID-19 pandemic. We will conduct an online survey with 3.000 participants using mobile website technology.

Study Overview

• Status: Completed
• Conditions: Covid19; Influenza A; Respiratory Disease
• Intervention / Treatment: Other: Cross-sectional survey

• Study Type: Observational
• Enrollment (Actual): 1287

Contacts and Locations

Study Locations

• Germany
  • Berlin, Germany, 14169
    • Charité University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The study is advertised via a website, thus all interested people can participate in this survey.

Description

Inclusion Criteria:

- Present declaration of consent

Exclusion Criteria:

- Lack of consent to participate in the study

Study Plan

How is the study designed?

Design Details

• Observational Models: Other
• Time Perspectives: Cross-Sectional

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Online survey with 3.000 participants using mobile website technology	Other: Cross-sectional survey; No intervention.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
SARS-CoV-2 infection	Assessed retrospectively (last 6 months) with self-designed question

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Influenza virus infection		Assessed retrospectively (last 6 months) with self-designed question
Other respiratory infections		Assessed retrospectively (last 6 months) with self-designed question
Dietary habits		Assessed retrospectively (last 6 months) with self-designed question
Sports activity		Assessed retrospectively (last 6 months) with self-designed question
Time spent in nature		Assessed retrospectively (last 6 months) with self-designed question
Use of hydrotherapy/Kneipp applications		Assessed retrospectively (last 6 months) with self-designed question
Use of anthroposophic medicine		Assessed retrospectively (last 6 months) with self-designed question
Use of digital health services		Assessed retrospectively (last 6 months) with self-designed question
Use of phytotherapy		Assessed retrospectively (last 6 months) with self-designed question
Use of dietary supplements		Assessed retrospectively (last 6 months) with self-designed question
WHO-5 Well-Being Index	The scale ranges from 0 to 100, where 0 is the lowest level of well-being / lowest quality of life and 100 is the highest level of well-being / highest quality of life.	Assessed when filling out the questionnaire (Baseline)
Numeric analog scale (NAS) stress	The NAS ranges from 0 to 10, where 0 is the lowest level of stress and 10 is the highest level of stress.	Assessed retrospectively (last 6 months) with self-designed question
Numeric analog scale (NAS) anxiety	The NAS ranges from 0 to 10, where 0 is the lowest level of anxiety and 10 is the highest level of anxiety.	Assessed retrospectively (last 6 months) with self-designed question
Numeric analog scale (NAS) depression	The NAS ranges from 0 to 10, where 0 is the lowest level of anxiety and 10 is the highest level of anxiety.	Assessed retrospectively (last 6 months) with self-designed question
Use of relaxation / mind body approaches		Assessed retrospectively (last 6 months) with self-designed question
Alcohol consumption		Assessed retrospectively (last 6 months) with self-designed question
Cigarette consumption		Assessed retrospectively (last 6 months) with self-designed question
Self-efficacy	The scale ranges from 0 to 100, where 0 is the lowest level of self-efficacy and 100 is the highest level of self-efficacy.	Assessed when filling out the questionnaire (Baseline)
Sick leave		Assessed retrospectively (last 6 months) with self-designed question

Other Outcome Measures

Outcome Measure	Time Frame
Qualitative interviews	Conducted 1 month after completion of the questionnaire (once)

Collaborators and Investigators

• Sponsor: Charite University, Berlin, Germany

Study record dates

Study Major Dates

• Study Start (Actual): January 6, 2021
• Primary Completion (Actual): March 5, 2021
• Study Completion (Actual): March 5, 2021

Study Registration Dates

• First Submitted: November 23, 2020
• First Submitted That Met QC Criteria: November 27, 2020
• First Posted (Actual): December 4, 2020

Study Record Updates

• Last Update Posted (Actual): September 29, 2022
• Last Update Submitted That Met QC Criteria: September 28, 2022
• Last Verified: September 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Respiration Disorders; Respiratory Tract Diseases
• Other Study ID Numbers: AtemNHK

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: No

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No